Special issue on

Research progress of in vitro diagnosis tests on COVID-19

CALL FOR PAPERS

Submission Deadline: August 31, 2023

Publication Date: Jan 2024

This Issue is now open for submissions. Manuscripts should be submitted online at aber.apacsci.com by registering and logging in to this website. Then you can submit the manuscripts.

Papers are published upon acceptance, regardless of the Special Issue publication date.

In our journal *In Vitro Diagnosis*, a special issue is calling for papers about IVD tests on COVID-19.

As COVID-19 swept the world, governments and companies raced to develop tools to slow the spread of SARS-CoV-2. COVID-19 testing is an important component of the fight against the pandemic and test developers have answered the call to provide tests to meet the demand.

In vitro diagnostics (IVD) are tests performed on samples such as blood or tissue taken from the human body. In vitro diagnostics can detect diseases or other conditions and can be used to monitor a person's overall health to help cure, treat or prevent disease. In terms of which is the best IVD test method for covid-19, the following are arguably the best: Lateral flow tests, which are suitable for high volumes in low-cost and non-laboratory environments; PCR, which is for the accuracy of the results; Gene sequencing, which is for the detection of different variants of viruses.

The current pandemic has demonstrated the value of IVD testing, and each of these methods will continue to play an important role in helping to address this emergency. Rather than asking which is the best IVD test method, the question we should be asking is which is the best IVD test method for a particular situation. Each test method has different equipment requirements and provides different information. This issue would like to solicit papers on in vitro diagnostics on COVID-19. Potential topics are suggested but not limited to **Fujifilm IVD, Rapid POC CE-IVD test, COVID-19 IVD devices, serology test for COVID-19, antibody test for COVID-19, etc.**